Business PR Newswire BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis rvrisingnetwork October 27, 2025 0 Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained... Read More Read more about BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
